GLB-001
A First-in-human, Phase 1, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 48 patients (estimated)
- Sponsors
- GluBio Therapeutics Inc.
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor), High Risk
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1815
- NCT Identifier
- NCT06146257
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.